---
title: "SSY Group says China grants NMPA registration approval for Gadobutrol bulk drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293263533.md"
description: "SSY Group announced that China's National Medical Products Administration (NMPA) has granted registration approval for its gadobutrol bulk drug. This approval clears the substance for use in marketed contrast-agent preparations. Gadobutrol is a macrocyclic MRI contrast agent used in adults and children, including full-term newborns. The company also highlighted its development of an integrated gadolinium franchise covering both bulk drugs and injection products."
datetime: "2026-07-20T23:54:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293263533.md)
  - [en](https://longbridge.com/en/news/293263533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293263533.md)
generator: "portal-rs"
---

# SSY Group says China grants NMPA registration approval for Gadobutrol bulk drug

-   SSY Group won China NMPA registration for its gadobutrol bulk drug, clearing it for use in marketed contrast-agent preparations. \* Gadobutrol is a macrocyclic MRI contrast agent used in adults and children, including full-term newborns. \* The group flagged development of an integrated gadolinium franchise spanning bulk drugs and injection products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260721-12250432), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group Wins China Approval for New Letermovir Injection](https://longbridge.com/en/news/298535677.md)
- [Huatai Securities Sticks to Their Buy Rating for SSY Group (LJUIF)](https://longbridge.com/en/news/297389381.md)
- [HK Policy Address Said to Extend HKD20,000 Newborn Bonus, Introduce Progressive Child Tax Allowance to Encourage Birth Rate](https://longbridge.com/en/news/298889663.md)
- [Pulse Radiology Institute and DeVry University Partner to Address Nationwide MRI Technologist Shortage](https://longbridge.com/en/news/299085656.md)
- [The AI doomsdayers aren't new. You just weren't paying attention.](https://longbridge.com/en/news/298706050.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**